At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 11, 2026 at 07:14 ET
C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per share), beating the Street consensus of -$0.23 by 21.7%. Cash increased to $300.4M following a $33.5M ATM raise and $20M Roche upfront, extending runway to end 2028. Clinical progress remains on track with Phase 2 MOMENTUM enrollment expected to complete in Q1 2027 and data in 2H 2027.
- Q2 2026 revenue $6.6M vs $6.5M YoY (up 2.7%)
- Net loss $23.6M vs $26.0M YoY; EPS -$0.18 vs -$0.37 YoY
- EPS beat consensus of -$0.23 by 21.7%
- Cash $300.4M, up from $268.3M QoQ; runway to end 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access